ALX Oncology Holdings Management
Management criteria checks 2/4
ALX Oncology Holdings' CEO is Jason Lettmann, appointed in Sep 2023, has a tenure of 4.42 years. total yearly compensation is $5.32M, comprised of 4.1% salary and 95.9% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $218.66K. The average tenure of the management team and the board of directors is 2.6 years and 3.9 years respectively.
Key information
Jason Lettmann
Chief executive officer
US$5.3m
Total compensation
| CEO salary percentage | 4.1% |
| CEO tenure | less than a year |
| CEO ownership | 0.2% |
| Management average tenure | 2.6yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
Sep 12ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
Jun 27ALX Oncology: Trying To Justify The Hype
Apr 18Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?
Mar 12
ALX Oncology GAAP EPS of -$0.81 misses by $0.18
Aug 08ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer
Aug 01ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer
Jun 29ALX Oncology Is Turning Into An Also-Ran In Anti-CD47
Feb 15ALX Oncology Stock: Attractive After Recent Data And Slump In Price
Nov 30ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space
Sep 08Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation
Jul 08Dosing underway in ALX Oncology's ALX148 combo study in head and neck cancer
May 10We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate
Mar 25Here's What ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) Shareholder Ownership Structure Looks Like
Feb 01
ALX Oncology: All Their Eggs In The Proverbial Basket
Jan 07ALX Oncology (ALXO) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 11ALX Oncology prices upsized stock offering at $76
Dec 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$171m |
| Mar 31 2024 | n/a | n/a | -US$166m |
| Dec 31 2023 | US$5m | US$217k | -US$161m |
| Sep 30 2023 | n/a | n/a | -US$146m |
| Jun 30 2023 | n/a | n/a | -US$130m |
| Mar 31 2023 | n/a | n/a | -US$129m |
| Dec 31 2022 | US$116k | n/a | -US$123m |
| Sep 30 2022 | n/a | n/a | -US$121m |
| Jun 30 2022 | n/a | n/a | -US$110m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$537k | n/a | -US$83m |
| Sep 30 2021 | n/a | n/a | -US$74m |
| Jun 30 2021 | n/a | n/a | -US$60m |
| Mar 31 2021 | n/a | n/a | -US$58m |
| Dec 31 2020 | US$352k | n/a | -US$51m |
Compensation vs Market: Jason's total compensation ($USD5.32M) is above average for companies of similar size in the US market ($USD677.23K).
Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.
CEO
Jason Lettmann (47 yo)
less than a year
Tenure
US$5,320,096
Compensation
Mr. Jason W. Lettmann had been an Independent Director of ALX Oncology Holdings Inc. since April 2020 until September 6, 2023 and previously served as a Director from March 2015 to May 2017 also serves as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$5.32m | 0.22% $ 218.7k | |
| Founder | 9.4yrs | US$2.75m | 0.88% $ 863.0k | |
| Chief Financial Officer | 4.7yrs | US$1.30m | 0.12% $ 114.3k | |
| Chief Medical Officer & Director | 8.3yrs | US$1.37m | 0.49% $ 477.7k | |
| Vice President of Operations | no data | no data | no data | |
| Senior VP of Finance & Chief Accounting Officer | 3.3yrs | US$7.23m | 0.066% $ 64.8k | |
| Manager of Investor Relations & Corporate Communications | no data | no data | no data | |
| General Counsel | 2.3yrs | no data | no data | |
| Senior Vice President of Clinical Development | 2.8yrs | no data | no data | |
| Senior Vice President of Drug Safety & Pharmacovigilance | 2.3yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | less than a year | no data | no data | |
| Senior Vice President of Clinical Operations | less than a year | no data | no data |
2.6yrs
Average Tenure
56yo
Average Age
Experienced Management: ALXO's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.4yrs | US$5.32m | 0.22% $ 218.7k | |
| Founder | 9.4yrs | US$2.75m | 0.88% $ 863.0k | |
| Chief Medical Officer & Director | 3.5yrs | US$1.37m | 0.49% $ 477.7k | |
| Chairman | 9.5yrs | US$206.61k | 0.32% $ 313.0k | |
| Chair of the Scientific Advisory Board | 3.9yrs | no data | no data | |
| Independent Director | 1.8yrs | US$105.66k | 0% $ 0 | |
| Member of the Scientific Advisory Board | 3.9yrs | no data | no data | |
| Independent Director | 4.4yrs | US$181.02k | 0.0057% $ 5.6k | |
| Member of the Scientific Advisory Board | 3.9yrs | no data | no data |
3.9yrs
Average Tenure
55.5yo
Average Age
Experienced Board: ALXO's board of directors are considered experienced (3.9 years average tenure).